Wanlong Wu

791 total citations
31 papers, 475 citations indexed

About

Wanlong Wu is a scholar working on Epidemiology, Rheumatology and Pathology and Forensic Medicine. According to data from OpenAlex, Wanlong Wu has authored 31 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Epidemiology, 13 papers in Rheumatology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Wanlong Wu's work include Inflammatory Myopathies and Dermatomyositis (17 papers), Eosinophilic Disorders and Syndromes (6 papers) and Systemic Sclerosis and Related Diseases (6 papers). Wanlong Wu is often cited by papers focused on Inflammatory Myopathies and Dermatomyositis (17 papers), Eosinophilic Disorders and Syndromes (6 papers) and Systemic Sclerosis and Related Diseases (6 papers). Wanlong Wu collaborates with scholars based in China, United States and France. Wanlong Wu's co-authors include Shuang Ye, Wenwen Xu, Danting Zhang, Kaiwen Wang, Zhiwei Chen, Yakai Fu, Li Guo, Xiaodong Wang, Zhiwei Chen and Suzana Jordan and has published in prestigious journals such as Scientific Reports, Free Radical Biology and Medicine and Journal of Bone and Mineral Research.

In The Last Decade

Wanlong Wu

27 papers receiving 473 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wanlong Wu China 12 274 207 181 142 104 31 475
Eun Bong Lee South Korea 11 214 0.8× 215 1.0× 77 0.4× 76 0.5× 151 1.5× 14 509
Sabrina Hoa Canada 12 140 0.5× 71 0.3× 124 0.7× 229 1.6× 93 0.9× 24 397
Éva Szekanecz Hungary 11 287 1.0× 245 1.2× 63 0.3× 187 1.3× 69 0.7× 19 548
Z. Amoura France 9 76 0.3× 274 1.3× 136 0.8× 70 0.5× 94 0.9× 22 480
L Origgi Italy 11 73 0.3× 175 0.8× 188 1.0× 248 1.7× 148 1.4× 23 511
Solène Tatibouet Canada 12 226 0.8× 123 0.6× 187 1.0× 566 4.0× 209 2.0× 16 648
Andrea Seaman United States 13 121 0.4× 311 1.5× 48 0.3× 66 0.5× 107 1.0× 17 432
Belén Atienza‐Mateo Spain 15 75 0.3× 271 1.3× 302 1.7× 94 0.7× 118 1.1× 50 552
D. Prieto-Peña Spain 14 60 0.2× 347 1.7× 408 2.3× 81 0.6× 85 0.8× 61 576
Satoshi Ebata Japan 15 241 0.9× 97 0.5× 218 1.2× 449 3.2× 211 2.0× 36 655

Countries citing papers authored by Wanlong Wu

Since Specialization
Citations

This map shows the geographic impact of Wanlong Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wanlong Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wanlong Wu more than expected).

Fields of papers citing papers by Wanlong Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wanlong Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wanlong Wu. The network helps show where Wanlong Wu may publish in the future.

Co-authorship network of co-authors of Wanlong Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Wanlong Wu. A scholar is included among the top collaborators of Wanlong Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wanlong Wu. Wanlong Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Wenwen, et al.. (2025). Spontaneous pneumomediastinum and/or pneumothorax in anti-MDA5 dermatomyositis: a refined staging system. Respiratory Research. 26(1). 281–281.
2.
Wang, Haiting, Shaoying Yang, Huihua Ding, et al.. (2025). Rituximab as the first-line treatment in newly diagnosed systemic lupus erythematosus. Frontiers in Immunology. 16. 1599473–1599473. 2 indexed citations
3.
Fu, Yakai, Zhiwei Chen, Jie Chen, et al.. (2025). Efficacy of JAK inhibitor combined with protein A immunoadsorption in MDA5+ dermatomyositis with RPILD: A real-world study. Med. 6(10). 100802–100802. 1 indexed citations
4.
Lian, Xinyue, Chengqiang Xia, Zhiwei Chen, et al.. (2025). Muscle Visualization and Evaluation Methods for Immune Checkpoint Inhibitor-Related Myositis. Journal of Visualized Experiments.
5.
Ye, Jiaqi, Wanlong Wu, Haixi Wu, et al.. (2025). A Novel Tool for Predicting Malignant Disease in Adult Patients With Dermatomyositis. JAMA Dermatology. 162(2). 176–176.
6.
Zhang, Yan, et al.. (2025). High‐Frequency Ultrasound and Shear Wave Elastography of Dermatofibrosarcoma Protuberans: A Novel Approach for Early Detection. Journal of Clinical Ultrasound. 53(5). 1035–1044. 1 indexed citations
7.
Wu, Wanlong, Runci Wang, Yi Chen, et al.. (2024). Anti-synthetase syndrome is associated with a higher risk of hospitalization among patients with idiopathic inflammatory myopathy and COVID-19. Frontiers in Immunology. 15. 1295472–1295472. 1 indexed citations
8.
Li, Jia, et al.. (2023). [68Ga]Ga-FAPI-04 and [18F]FDG PET/ CT in a patient with MDA5 dermatomyositis. European Journal of Nuclear Medicine and Molecular Imaging. 50(12). 3790–3791. 5 indexed citations
9.
Zhou, Yuhong, et al.. (2022). Differences in sex- and age-associated mortality in patients with anti-MDA5-positive dermatomyositis. Modern Rheumatology. 33(5). 975–981. 10 indexed citations
10.
Lv, Xia, Wenwen Xu, Yan Ye, et al.. (2022). Spontaneous Intramuscular Hemorrhage in Anti-MDA5 Positive Dermatomyositis: A Case Series and Literature Review. Frontiers in Medicine. 8. 802753–802753. 7 indexed citations
11.
Fu, Yakai, Wanlong Wu, Zhiwei Chen, et al.. (2022). Trisomy 8 Associated Clonal Cytopenia Featured With Acquired Auto-Inflammation and Its Response to JAK Inhibitors. Frontiers in Medicine. 9. 895965–895965. 7 indexed citations
12.
13.
Xu, Wenwen, Wanlong Wu, Yu Zheng, et al.. (2021). A Computed Tomography Radiomics-Based Prediction Model on Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis. Frontiers in Medicine. 8. 768052–768052. 25 indexed citations
14.
Xu, Wenwen, Wanlong Wu, Danting Zhang, et al.. (2021). A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis. Scientific Reports. 11(1). 17070–17070. 24 indexed citations
15.
Wu, Wanlong, Wenwen Xu, Wenjia Sun, et al.. (2021). Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study. Lara D. Veeken. 61(1). 230–239. 39 indexed citations
16.
Zheng, Yu, et al.. (2021). Utility of fractional exhaled nitric oxide in interstitial lung disease. Journal of Breath Research. 15(3). 36004–36004. 1 indexed citations
17.
Sun, Fangfang, Jie Chen, Wanlong Wu, et al.. (2020). Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study. Clinical Rheumatology. 39(10). 3099–3104. 14 indexed citations
18.
Sun, Fangfang, Yi Chen, Wanlong Wu, et al.. (2019). Varicella zoster virus infections increase the risk of disease flares in patients with SLE: a matched cohort study. Lupus Science & Medicine. 6(1). e000339–e000339. 14 indexed citations
19.
Wu, Wanlong, Suzana Jordan, Mike Oliver Becker, et al.. (2018). Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Annals of the Rheumatic Diseases. 77(9). 1326–1332. 87 indexed citations
20.
Xia, Zhidao, Wanlong Wu, & J T Triffitt. (2000). Effect of a herbal medicine on human bone and bone marrow fibroblastic cells in vivo and in vitro.. Journal of Bone and Mineral Research. 15. 1232–1232. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eun Bong Lee Breakdown of academic impact, for papers by Sabrina Hoa Breakdown of academic impact, for papers by Éva Szekanecz Breakdown of academic impact, for papers by Z. Amoura Breakdown of academic impact, for papers by L Origgi Breakdown of academic impact, for papers by Solène Tatibouet Breakdown of academic impact, for papers by Andrea Seaman Breakdown of academic impact, for papers by Belén Atienza‐Mateo Breakdown of academic impact, for papers by D. Prieto-Peña Breakdown of academic impact, for papers by Satoshi Ebata
Rankless by CCL
2026